Trial Profile
INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Crohn's disease
- Focus Adverse reactions
- Acronyms INFORM
- Sponsors Biogen; Elan Pharmaceuticals
- 06 Jul 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
- 03 Nov 2014 Planned End Date changed from 1 Jun 2017 to 1 Aug 2050 as reported by ClinicalTrials.gov record.
- 03 Nov 2014 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2050 as reported by ClinicalTrials.gov record.